Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
暂无分享,去创建一个
S. Servaes | A. Naranjo | J. Maris | W. London | M. Diccianni | A. Yu | B. Shulkin | M. Parisi | R. Bagatell | Julie R. Park | P. Sondel | R. Mody | Collin Van Ryn | J. Bender | Sabah E. Servaes | Sabah Servaes
[1] S. Asgharzadeh,et al. More than the genes, the tumor microenvironment in neuroblastoma. , 2016, Cancer letters.
[2] J. Boudreau,et al. KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Naranjo,et al. A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study. , 2016 .
[4] A. Naranjo,et al. Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Children’s Oncology Group (COG) study. , 2016 .
[5] Sara M. Federico,et al. Improved clinical responses with the concomitant use of an anti-GD2 monoclonal antibody and chemotherapy in newly diagnosed children with high-risk (HR) neuroblastoma (NB): Preliminary results of a phase II study. , 2016 .
[6] A. Aguzzi,et al. Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma , 2016, PloS one.
[7] Gudrun Schleiermacher,et al. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] I. Ostrovnaya,et al. Key role for myeloid cells: Phase II results of anti‐GD2 antibody 3F8 plus granulocyte‐macrophage colony‐stimulating factor for chemoresistant osteomedullary neuroblastoma , 2014, International journal of cancer.
[9] N. Cheung,et al. GD2-targeted immunotherapy and radioimmunotherapy. , 2014, Seminars in oncology.
[10] S. Keir,et al. Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program , 2014, Pediatric blood & cancer.
[11] R. Norris,et al. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study , 2014, Pediatric blood & cancer.
[12] C. Porta,et al. Targeting PI3K/Akt/mTOR Signaling in Cancer , 2014, Front. Oncol..
[13] Daniel J Sargent,et al. Randomized Phase II Clinical Trials , 2014, Journal of biopharmaceutical statistics.
[14] John M Maris,et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. , 2013, The Lancet. Oncology.
[15] N. Cheung,et al. Ifosfamide, carboplatin, and etoposide for neuroblastoma , 2013, Cancer.
[16] S. Keir,et al. Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program , 2012, Pediatric blood & cancer.
[17] A. Naranjo,et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] A. Naranjo,et al. Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children's Oncology Group , 2011, Clinical Cancer Research.
[19] D. Greenblatt,et al. Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] V. Pistoia,et al. Cytokines in neuroblastoma: from pathogenesis to treatment. , 2011, Immunotherapy.
[21] J. Maris,et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Maris,et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Helen X. Chen,et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.
[24] B. Brumback,et al. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] L. Qin,et al. Differential impact of high‐dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma , 2010, Cancer.
[26] S. Grupp,et al. Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. , 2010, European journal of cancer.
[27] Louis M. Weiner,et al. Monoclonal antibodies: versatile platforms for cancer immunotherapy , 2010, Nature Reviews Immunology.
[28] S. Parodi,et al. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. , 2009, European journal of cancer.
[29] M. Smyth,et al. Immunogenic anti-cancer chemotherapy as an emerging concept. , 2008, Current opinion in immunology.
[30] J. Dufour,et al. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. , 2008, Journal of hepatology.
[31] S. Eksborg,et al. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo , 2008, Oncogene.
[32] S. Keir,et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program , 2008, Pediatric blood & cancer.
[33] J. Chewning,et al. Hierarchy of the Human Natural Killer Cell Response Is Determined by Class and Quantity of Inhibitory Receptors for Self-HLA-B and HLA-C Ligands1 , 2007, The Journal of Immunology.
[34] F. Berthold,et al. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial , 2007, Journal of Cancer Research and Clinical Oncology.
[35] F. Berthold,et al. Topotecan and Etoposide in the Treatment of Relapsed High-risk Neuroblastoma: Results of a Phase 2 Trial , 2007, Journal of pediatric hematology/oncology.
[36] Su-Chun Cheng,et al. Evaluation of semi‐quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma , 2006, Pediatric blood & cancer.
[37] N. Cheung,et al. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] A. Vickers,et al. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] N. Schmitz,et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.
[40] Boris Freidlin,et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] A. Mackensen,et al. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy , 2005, Cancer Immunology, Immunotherapy.
[42] G. Mills,et al. Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer Cells , 2004, Clinical Cancer Research.
[43] L. Moretta,et al. Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[44] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[45] G. Severi,et al. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma , 2003, Cancer.
[46] W. Weng,et al. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] A. Nowak,et al. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. , 2003, Cancer research.
[48] Seth M Steinberg,et al. Early selection in a randomized phase II clinical trial , 2002, Statistics in medicine.
[49] G. Salles,et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.
[50] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[51] S. Holden,et al. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[52] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[53] M. Uttenreuther-Fischer,et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] J. Månsson,et al. Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. , 1994, Biochimica et biophysica acta.
[55] F. Berthold,et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.
[56] N. Cheung,et al. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. , 1985, Cancer research.
[57] D. Cheresh,et al. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. , 1984, Cancer research.
[58] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[59] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[60] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[61] G. Zhu,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.
[62] Pierre Morel,et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.